Biomarkers of Coronary Microvascular Reserve Derived From Dynamic Cardiovascular Responses

Abstract

Coronary microvascular dysfunction (CMD) is increasingly recognized as a key contributor to ischemic heart disease, particularly in patients without obstructive coronary artery disease. Biomarkers reflecting coronary microvascular reserve (CMR), particularly those derived from dynamic cardiovascular responses, provide valuable insights into the physiological integrity of the coronary microcirculation. This review comprehensively examines current and emerging biomarkers of CMR, their pathophysiological underpinnings, clinical implications, and recent advances, with a focus on their utility in diagnosis, risk stratification, and management of CMD. We discuss the epidemiology, risk factors, and diagnostic modalities, and provide evidence-based recommendations for clinical practice based on the latest guidelines.

Introduction

Coronary microvascular reserve refers to the capacity of the coronary microcirculation to increase blood flow above baseline in response to increased myocardial demand. Impairment of CMR, often manifesting as CMD, has emerged as a significant cause of angina and adverse cardiovascular outcomes, especially in populations with non-obstructive coronary artery disease. Traditional diagnostic approaches often overlook microvascular involvement, underscoring the need for reliable biomarkers that can be assessed through dynamic cardiovascular testing. This review explores the mechanistic basis, clinical utility, and future scope of CMR biomarkers derived from dynamic cardiovascular responses, aiming to bridge the gap between pathophysiological understanding and clinical application.

Epidemiology / Disease Burden

CMD is a prevalent yet underdiagnosed condition, affecting up to 50% of women and a significant proportion of men presenting with angina and non-obstructive coronary arteries. Epidemiological studies highlight that CMD confers a two- to fivefold increased risk of major adverse cardiovascular events, including myocardial infarction and heart failure. The burden is particularly high among patients with diabetes, metabolic syndrome, and systemic inflammatory diseases. Despite its prevalence, CMD is often under-recognized due to the lack of overt epicardial coronary stenosis, leading to delays in diagnosis and suboptimal management.

Pathophysiology

The coronary microcirculation consists of small arterioles and capillaries that regulate myocardial blood flow. CMD results from structural and functional alterations in these vessels, including endothelial dysfunction, smooth muscle cell hyperreactivity, extravascular compression, and impaired autoregulation. These changes reduce CMR, limiting the heart's ability to augment perfusion during stress. Dynamic cardiovascular responses, such as those elicited by pharmacological vasodilators or exercise, provide a window into microvascular health, and the measurement of biomarkers during these stimuli reflects underlying pathophysiology.

Risk Factors

Risk factors for impaired CMR mirror those of atherosclerotic disease but also encompass unique mechanisms. Traditional risk factors include hypertension, hyperlipidemia, smoking, diabetes mellitus, and obesity. Additionally, systemic inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis), microvascular rarefaction, autonomic dysfunction, and hormonal factors particularly in women contribute to microvascular impairment. Genetic predispositions and chronic kidney disease further increase susceptibility to CMD and reduced CMR.

Clinical Features

Patients with reduced CMR present with angina-like chest pain, often indistinguishable from typical angina despite the absence of significant epicardial stenosis on coronary angiography. Symptoms may be exacerbated by exertion or emotional stress and may persist despite revascularization of epicardial disease. CMD may also contribute to heart failure with preserved ejection fraction (HFpEF), arrhythmias, and unexplained exertional dyspnea. The non-specific nature of symptoms necessitates high clinical suspicion and targeted diagnostic strategies.

Diagnosis

Diagnosis of impaired CMR relies on both invasive and non-invasive modalities. Invasive tests include measurement of coronary flow reserve (CFR) or the index of microcirculatory resistance (IMR) using pressure and flow wires during vasodilator challenge. Non-invasive imaging, such as positron emission tomography (PET), cardiac magnetic resonance (CMR), and transthoracic Doppler echocardiography, can quantify myocardial blood flow and reserve. Biomarkers derived from dynamic cardiovascular responses such as changes in flow-mediated dilation, circulating endothelial microparticles, adenosine-induced hyperemia, and stress-induced lactate production are under investigation for their diagnostic utility. Integration of these biomarkers with functional imaging may enhance diagnostic accuracy and risk stratification.

Treatment & Management

Management of impaired CMR is multifaceted, targeting both underlying risk factors and symptomatic relief. Lifestyle modification, optimal control of blood pressure, lipids, and glycemic status are foundational. Pharmacological therapies include beta-blockers, calcium channel blockers, ACE inhibitors, statins, and, in selected cases, ranolazine or ivabradine. Recent evidence supports the use of anti-anginal agents that improve microvascular function rather than solely targeting epicardial stenosis. Patient education and psychosocial support are also critical, given the chronic nature and impact of CMD on quality of life.

Recent Advances / Emerging Therapies

Recent advances focus on the identification and validation of novel biomarkers reflecting CMR. Dynamic measurements of nitric oxide bioavailability, endothelin-1, and microRNAs during cardiovascular stress are under active investigation. Artificial intelligence algorithms applied to imaging-derived perfusion metrics and circulating proteomic signatures may soon enable personalized risk prediction. Emerging therapies target microvascular inflammation, oxidative stress, and endothelial repair, with several agents in clinical trials showing promise for improving CMR and reducing symptoms. Integration of biomarker data with clinical and imaging findings is expected to refine patient selection for targeted therapies.

Guideline Recommendations

Recent guidelines from the European Society of Cardiology and American College of Cardiology emphasize the importance of recognizing CMD and assessing CMR in patients with angina and non-obstructive coronary arteries. The use of non-invasive imaging or invasive functional testing is recommended for diagnosis, with increasing attention to the role of dynamic biomarkers. Guideline-directed therapy includes aggressive risk factor modification and tailored pharmacological management, with ongoing research into outcome-driven strategies based on biomarker-guided approaches.

Conclusion

Biomarkers of coronary microvascular reserve derived from dynamic cardiovascular responses represent a rapidly evolving frontier in cardiovascular medicine. Their integration into clinical practice offers the potential for earlier diagnosis, refined risk stratification, and personalized management of CMD. Continued research into mechanistic pathways, biomarker validation, and therapeutic interventions will further illuminate their role and improve outcomes for patients suffering from coronary microvascular disease.